Search Results 491-500 of 17379 for alopecia

  1. Mayo Clinic

    ... . IMG-20076824. Home; WF619106-2-Quadriceps-stretch-468x263. 5X Challenge is here! 5X My Gift! Your gift today can have 5X the impact on AI research and ...

  2. Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

    *Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...

  3. Hidradenitis suppurativa - Diagnosis and treatment - Mayo Clinic

    Uso de la espironolactona en dermatología: Acné, hidradenitis supurativa, alopecia femenina e hirsutismo. Actas Dermosifiliogr. 2020; doi: 10.1016/j.ad ...

  4. Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer - Mayo Clinic

    Received chemotherapy or radiotherapy within 3 weeks prior to randomization or those who have not recovered to =< grade 1 adverse events (other than alopecia) ...

  5. Loncastuximab Tesirine in WM - Clinical Trials

    Participants with ongoing >grade 1 toxicities from prior therapy (alopecia any grade and/or grade 2 neuropathy are permitted). - Participants with ...

  6. Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors - Mayo Clinic

    ... alopecia -Receiving any other investigational agents =< 28 days prior to registration -Known brain metastases (even if treated) -Known portal hypertension ...

  7. A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer - Mayo Clinic

    Any persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 drug-related toxicity (except alopecia, erectile impotence ...

  8. Mayo Clinic

    ... . VID-20510545. Home; The Future of Healthcare - Dr Anton Decker. Fuel groundbreaking medical research! Give Today. Your donation powers the future of ...

  9. Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    ... alopecia), or deemed irreversible from the effects of prior cancer therapy; Major surgery, serious infection, or infection requiring systemic antibiotic ...

  10. Mayo Clinic

    ... . VID-20273348. Home; Why Choose Mayo Executive Health Program. 5X Challenge is here! 5X My Gift! Your gift today can have 5X the impact on AI research ...